Saturday 17 October 2026 Export APVO’s income statement to Excel — free account

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million. In the quarter to June 2026, EPS grew 96.5% and free cash flow grew 23.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.62 0.08 −4.71%

Follow APVO

Alert me

Market cap: $3.1M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: —
F-score: 4/9
Altman Z: 256174.47
Beneish M: 3.69
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.02

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 3.08

Revenue 12.99

Net Income (26.41)

Free Cash Flow (25.34)

Net Debt (9.80)

Current Ratio 2.08

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.49)

P/S ratio 0.15

P/B ratio 0.32

Past 5Y EPS Growth —

This Y EPS Growth 80.47%

Next Y EPS Growth 61.33%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 58.56%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 18.77%

10-year low 10-year high

P/S against its own 10 years 14.06%

10-year low 10-year high

P/B against its own 10 years 12.99%

10-year low 10-year high

EV/FCF against its own 10 years 32.00%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	17	9	22	10
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	1	0	—	—
	19	11	23	11

	2023	2024	2025	Q'26
Payables	4	1	1	1
ST’ Debt	—	—	—	—
Other	1	1	—	—
	7	6	6	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	(26.64%)	(54.21%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(15.03%)	0.93%	(1.11%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	3	—	—	—	3
’21	2	3	3	4	12
’20	—	0	1	2	4
’19	7	7	9	9	32
’18	4	7	6	6	23
’17	2	4	6	3	15

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(5)	—	—	—
’25	(7)	(7)	(7)	(5)	(26)
’24	(7)	(6)	(5)	(6)	(24)
’23	5	(5)	(6)	(5)	(12)
’22	(5)	(3)	(7)	(6)	(21)
’21	(8)	(5)	(5)	(4)	(22)
’20	(11)	(5)	(7)	(6)	(29)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(5)	—	—	—
’25	(7)	(7)	(7)	(5)	(26)
’24	(7)	(6)	(5)	(6)	(24)
’23	5	(5)	(6)	(5)	(12)
’22	(5)	(3)	(7)	(6)	(21)
’21	(8)	(5)	(5)	(4)	(22)
’20	(11)	(5)	(7)	(6)	(29)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(6.41)	(5.31)	—	—	—
’25	(1.58k)	(151.08)	(40.11)	1.68k	(87.27)
’24	(129.68k)	(21.77k)	(6.26k)	129.67k	(31.43k)
’23	223.92k	(706.20k)	(287.07k)	(66.53k)	(815.28k)
’22	(889.92k)	3.20m	(861.21k)	(0.94)	901.40k
’21	(941.59k)	(1.00m)	(821.02k)	(1.25)	(3.49m)
’20	510.99k	(2.10)	(1.21m)	(1.92)	(5.23)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	13,866,653.00	9,419,478.00	9,107,683.00	4,020,508.75	1,723,075.25	3,739,190.50	1,136,995.25	89,084.16	1,314.00	9.07	Analyst estimates 2026–2028 Powerpack
	High	68,020,448.00	36,923,040.00	52,102,512.00	16,410,240.00	35,164,800.00	25,324,516.00	5,010,984.00	1,512,086.38	143,856.00	1,976.40
People
People	Employees	118	121	118	80	58	54	45	40	42	36
	Revenue/emp, $m	0.08	0.12	0.20	0.41	0.07	0.23	0.07	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	10	15	23	32	4	12	3	—	—	—
	Gross margin, %	(24.86)	65.82	51.39	(6.89)	100.00	100.00	100.00	—	—	—
	EBT	(140)	(56)	(54)	(43)	(31)	(29)	7	(19)	(24)	(26)
	EBT margin, %	(1,397.93)	(381.31)	(232.75)	(132.82)	(717.64)	(239.25)	225.24	0.00	0.00	0.00
	Net income	(112)	7	(54)	(40)	(18)	(28)	8	(17)	(24)	(26)
	Depreciation	3	3	2	2	1	1	1	1	0	0
Per share, $
Per share, $	Revenue	0.49	0.69	1.03	11.12	1.27	2.62	0.61	0.00	0.00	0.00
	Earnings	(44,628,780.00)	2,653,603.00	(2.39)	(7,963,367.00)	(2,895,514.00)	(3,485,050.00)	901,404.90	(815,283.40)	(31,431.65)	(87.27)
	Cash flow	(1.82)	(1.95)	(2.29)	(14.53)	(8.65)	(4.62)	(4.12)	0.00	(29,731.25)	(81.12)
	Capex	(0.12)	(0.07)	(0.04)	(0.05)	(0.03)	(0.15)	(0.01)	0.00	0.00	0.00
	Free cash flow	(1.95)	(2.01)	(2.33)	(14.58)	(8.67)	(4.78)	(4.13)	0.00	(29,731.25)	(81.12)
	Book value	2.50	3.85	1.35	4.06	4.89	0.26	3.52	0.00	5,943.75	55.09
	Shares, m	20	21	23	3	3	5	5	0	0	0
Valuation, ×
Valuation, ×	P/E	0.00	6.38	0.00	0.00	0.00	0.00	0.92	—	—	—
	P/S	41,578,223.25	56,728,401.70	10,164,405.30	483,499.54	5,460,128.21	1,759,124.90	527,133.51	—	—	—
	P/B	8,210,231.36	10,136,221.27	7,711,054.96	1,323,846.41	4,389,424.51	17,782,206.63	380,818.33	—	—	—
	EV/Sales	41,578,219.60	56,728,397.46	10,164,404.99	483,499.87	5,460,126.90	1,759,122.38	527,132.03	—	—	—
	EV/FCF	(10,543,976.30)	(19,349,036.65)	(4,474,642.73)	(368,558.40)	(2,476,980.64)	(965,663.29)	(323,341.18)	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(37)	(42)	(51)	(42)	(29)	(22)	(21)	(12)	(24)	(26)
	Capex	(3)	(1)	(1)	0	0	(1)	0	—	—	—
	Free cash flow	(39)	(43)	(52)	(43)	(29)	(22)	(21)	(12)	(24)	(26)
Balance, $m
Balance, $m	Working capital	52	77	31	(8)	33	18	19	12	4	17
	Total debt	18	19	19	23	25	15	3	—	—	—
	Net debt	(37)	(62)	(11)	11	(17)	(31)	(19)	(17)	(9)	(22)
	Shareholders’ equity	51	82	30	12	17	1	18	12	5	17
Returns, %
Returns, %	ROA	(102.37)	6.68	(58.20)	(66.91)	(33.19)	(51.67)	17.68	(58.96)	(119.36)	(128.73)
	ROIC	(618.46)	(169.33)	(169.51)	(113.36)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(161.53)	10.52	(95.50)	(191.48)	(124.84)	(319.56)	83.66	(115.32)	(284.28)	(248.81)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Mar 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADXN Addex Therapeutics Ltd. Sponsored ADR	$3.2M	— (loss-making)	— (loss-making)	−100.78% (below 0%: shrinking)	n/m	−2.73% (below 0%: shrinking)	100.00%	0.00%	Compare
CLDI Calidi Biotherapeutics, Inc.	$3.2M	— (loss-making)	—	—	n/m	+11.16% (above 0%: growing)	—	0.00%	Compare
EOCN Eocene Ltd.	$3.2M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−67.74% (below 0%: shrinking)	0.00%	0.00%	Compare
SXTP 60 Degrees Pharmaceuticals Inc.	$3.2M	— (loss-making)	— (loss-making)	−32.48% (below 0%: shrinking)	n/m	−54.33% (below 0%: shrinking)	27.32%	(1,092.40%)	Compare
APVO Aptevo Therapeutics Inc.	$3.1M	0.0×	— (loss-making)	+28.62% (above 0%: growing)	n/m	+23.11% (above 0%: growing)	0.00%	0.00%
GRI GRI Bio, Inc.	$3.1M	0.0×	— (loss-making)	—	n/m	+54.33% (above 0%: growing)	0.00%	0.00%	Compare
REVB Revelation Biosciences, Inc.	$3.0M	— (loss-making)	—	—	n/m	−35.29% (below 0%: shrinking)	0.00%	0.00%	Compare
ARAV ARAVIVE, INC	$3.0M	— (loss-making)	— (loss-making)	−44.39% (below 0%: shrinking)	n/m	+48.19% (above 0%: growing)	100.00%	(323.44%)	Compare
DCOY Decoy Therapeutics Inc	$2.9M	0.0×	— (loss-making)	−84.61% (below 0%: shrinking)	n/m	−212.47% (below 0%: shrinking)	100.00%	(1,055.98%)	Compare
Median of peers	$3.1M	—	—	−84.61%	—	−19.01%	27.32%	0.00%

All 614 Biotechnology stocks →

Aptevo Therapeutics Inc. (APVO) key facts

Aptevo Therapeutics Inc. (APVO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million.
As of October 16, 2026, APVO traded at $1.62, a market capitalization of $3.1 million.
Return on equity was −248.8% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 256174.47 (safe zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.